Production of Mass-Separated Erbium-169 Towards the First Preclinical in vitro Investigations

Frontiers in Medicine

article

Zeynep Talip¹  Vadim Gadelshin²  Valentin N. Fedosseev²  Frederic Juget⁵  Claude Bailat⁵  Adelheid Fankhauser¹  Shane G. Wilkins²  Laura Lambert²  Bruce Marsh²  Dmitry Fedorov⁶  Eric Chevallay²  Francesca Borgna¹  Pascal Fernier²  Roger Schibli¹  Nicholas P. van der Meulen¹  Cristina Müller¹  Jiri Ulrich⁸  Charlotte Duchemin²  Joao P. Ramos²  Thierry Stora²  Ulli Köster^1,10  Youcef Nedjadi⁵ 

[1] Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute;European Organization for Nuclear Research (CERN);Institute of Physics, Johannes Gutenberg University;Institute of Physics and Technology, Ural Federal University;Institute of Radiation Physics, University Hospital and University of Lausanne;Petersburg Nuclear Physics Institute, National Research Center Kurchatov Institute;Department of Chemistry and Applied Biosciences;Laboratory of Radiochemistry, Paul Scherrer Institute;Institute for Nuclear and Radiation Physics, Catholic University of Leuven;Institut Laue-Langevin

关键词: Er-169;    electromagnetic isotope separation;    lanthanide-separation;    activity standardization;    in vitro studies;    laser resonance ionization;   

DOI  :  10.3389/fmed.2021.643175

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

The β − -particle-emitting erbium-169 is a potential radionuclide toward therapy of metastasized cancer diseases. It can be produced in nuclear research reactors, irradiating isotopically-enriched 168 Er 2 O 3 . This path, however, is not suitable for receptor-targeted radionuclide therapy, where high specific molar activities are required. In this study, an electromagnetic isotope separation technique was applied after neutron irradiation to boost the specific activity by separating 169 Er from 168 Er targets. The separation efficiency increased up to 0.5% using resonant laser ionization. A subsequent chemical purification process was developed as well as activity standardization of the radionuclidically pure 169 Er. The quality of the 169 Er product permitted radiolabeling and pre-clinical studies. A preliminary in vitro experiment was accomplished, using a 169 Er-PSMA-617, to show the potential of 169 Er to reduce tumor cell viability.

【 授权许可】

CC BY